Mylan wins US District Court ruling related to Copaxone patents

31 January 2017

The US District Court for the District of Delaware issued a decision finding all asserted claims of four Orange Book-listed patents relating to the top-selling multiple sclerosis drug Copaxone (glatiramer acetate) 40 mg/mL invalid based on obviousness, according to Netherlands-incorporated Mylan (Nasdaq: MYL),

The invalidated patents are US Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development and licensed to Israeli generics giant Teva Pharmaceuticals Industries (NYSE: TEVA).

Copaxone generates annual sales of around $4 billion for Teva, whose share plummeted as much as 9% in after-hours trading in the USA, and were down 6.3% at 12,210 new Israeli shekels on morning Tel Aviv trading. Mylan was up 2.6% at $37.29.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK